TY - JOUR
T1 - Patterns in Psychiatrists’ Prescription of Valproate for Female Patients of Childbearing Age With Bipolar Disorder in Japan
T2 - A Questionnaire Survey
AU - Tachibana, Masumi
AU - Hashimoto, Tasuku
AU - Tanaka, Mami
AU - Watanabe, Hiroyuki
AU - Sato, Yasunori
AU - Takeuchi, Takashi
AU - Terao, Takeshi
AU - Kimura, Shou
AU - Koyama, Akio
AU - Ebisawa, Sachie
AU - Shizu, Yuichiro
AU - Nagase, Teruyoshi
AU - Hirakawa, Junichi
AU - Hatta, Kotaro
AU - Nakazato, Michiko
AU - Iyo, Masaomi
N1 - Funding Information:
We would like to thank all responding psychiatrists participating in the present questionnaire survey, despite their busy schedule. We also want to express our appreciation to the Japanese Association of Neuro-Psychiatric Clinics: Tokyo branch and Chiba branch, the Japan Psychiatric Hospitals Association: Ibaraki branch, Chiba branch and Tokyo branch, and the Japanese Society of General Hospital Psychiatry. We also would like to thank Editage (www.editage.jp) for English language editing.
Publisher Copyright:
© Copyright © 2020 Tachibana, Hashimoto, Tanaka, Watanabe, Sato, Takeuchi, Terao, Kimura, Koyama, Ebisawa, Shizu, Nagase, Hirakawa, Hatta, Nakazato and Iyo.
PY - 2020/4/15
Y1 - 2020/4/15
N2 - Background: Accumulating evidence has shown that valproate has the greatest teratogenic potential for increasing the risk of major congenital malformations, such as neural tube defects, cleft palate, and neurodevelopmental disability. Although valproate is a pharmacological option for acute mania and is used as a stabilization drug for patients with bipolar disorder, some global guidelines state that valproate should not be used for girls or women of childbearing age with bipolar disorder. We investigated patterns in psychiatrists' prescription of valproate for bipolar female patients of childbearing age in Japan. Methods: From March to May 2018, we conducted a questionnaire survey among psychiatrists from all prefectures in Japan on psychiatric practice as it relates to major depression and bipolar disorder throughout women's life. The questionnaire had two parts: (1) assessment of participating psychiatrists' backgrounds and attitudes toward patients and (2) their patterns of prescription of psychotropics for female patients with mood disorders across generations and periods of pregnancy. Each question item had four response options: “not at all,” “rarely,” “sometimes,” and “frequently.” We examined patterns of prescription for childbearing-aged women (late adolescence/young adulthood aged 18–24 years, childbearing-age, older adults aged 25–49 years) and pregnant women. Results: In total, 571 psychiatrists (427 males, 123 females, and 21 unknowns) responded appropriately to the questionnaire, including 320 who examined at least one or more late adolescence/young adulthood bipolar women. Approximately 70% of psychiatrists answered that they frequently or sometimes prescribed valproate for bipolar women of childbearing age [late adolescence/young adulthood: not at all, n = 23 (7.5%); rarely, n = 69 (22.5%); sometimes, n =116 (37.8%); and frequently, n = 99 (32.2%); childbearing-age, older adults: not at all, n = 13 (2.7%); rarely, n = 67 (13.8%); sometimes, n = 185 (38.1%); and frequently, n = 220 (45.4%)]. The proportion of general hospital psychiatrists who answered “not at all” or “rarely” to the frequency of their valproate prescriptions was higher than that of psychiatrists working in other medical facilities (χ2(3) = 18.2, p < 0.001). Conclusion: Most psychiatrists frequently or sometimes prescribe valproate for women of childbearing age in Japan.
AB - Background: Accumulating evidence has shown that valproate has the greatest teratogenic potential for increasing the risk of major congenital malformations, such as neural tube defects, cleft palate, and neurodevelopmental disability. Although valproate is a pharmacological option for acute mania and is used as a stabilization drug for patients with bipolar disorder, some global guidelines state that valproate should not be used for girls or women of childbearing age with bipolar disorder. We investigated patterns in psychiatrists' prescription of valproate for bipolar female patients of childbearing age in Japan. Methods: From March to May 2018, we conducted a questionnaire survey among psychiatrists from all prefectures in Japan on psychiatric practice as it relates to major depression and bipolar disorder throughout women's life. The questionnaire had two parts: (1) assessment of participating psychiatrists' backgrounds and attitudes toward patients and (2) their patterns of prescription of psychotropics for female patients with mood disorders across generations and periods of pregnancy. Each question item had four response options: “not at all,” “rarely,” “sometimes,” and “frequently.” We examined patterns of prescription for childbearing-aged women (late adolescence/young adulthood aged 18–24 years, childbearing-age, older adults aged 25–49 years) and pregnant women. Results: In total, 571 psychiatrists (427 males, 123 females, and 21 unknowns) responded appropriately to the questionnaire, including 320 who examined at least one or more late adolescence/young adulthood bipolar women. Approximately 70% of psychiatrists answered that they frequently or sometimes prescribed valproate for bipolar women of childbearing age [late adolescence/young adulthood: not at all, n = 23 (7.5%); rarely, n = 69 (22.5%); sometimes, n =116 (37.8%); and frequently, n = 99 (32.2%); childbearing-age, older adults: not at all, n = 13 (2.7%); rarely, n = 67 (13.8%); sometimes, n = 185 (38.1%); and frequently, n = 220 (45.4%)]. The proportion of general hospital psychiatrists who answered “not at all” or “rarely” to the frequency of their valproate prescriptions was higher than that of psychiatrists working in other medical facilities (χ2(3) = 18.2, p < 0.001). Conclusion: Most psychiatrists frequently or sometimes prescribe valproate for women of childbearing age in Japan.
KW - bipolar disorder
KW - childbearing-age women
KW - congenital malformations
KW - pharmacoepidemiology
KW - pregnancy
KW - valproate
UR - http://www.scopus.com/inward/record.url?scp=85083996747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083996747&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2020.00250
DO - 10.3389/fpsyt.2020.00250
M3 - Article
AN - SCOPUS:85083996747
SN - 1664-0640
VL - 11
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 250
ER -